| First Author | Martinez de Lagran M | Year | 2022 |
| Journal | J Cell Mol Med | Volume | 26 |
| Issue | 15 | Pages | 4210-4215 |
| PubMed ID | 35762509 | Mgi Jnum | J:327075 |
| Mgi Id | MGI:7328029 | Doi | 10.1111/jcmm.17411 |
| Citation | Martinez de Lagran M, et al. (2022) Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome. J Cell Mol Med 26(15):4210-4215 |
| abstractText | An elevated activity of retrotransposons is increasingly recognized to be implicated in a wide range of neurodegenerative and neurodevelopmental diseases. Down syndrome (DS) is the most common genetic disorder associated with intellectual disability and a genetic form of Alzheimer's disease. For this reason, we hypothesized that treatment with reverse transcriptase inhibitors could ameliorate DS phenotypes. In this proof of concept study, we treated trisomic (Ts65Dn) mice, a model of DS, with lamivudine, a reverse transcriptase inhibitor. We detected a significant improvement of neurobehavioural phenotypes, and a complete rescue of the hippocampal-dependent recognition memory upon treatment with lamivudine. Despite clinical studies in patients with DS are warranted, this study lays the groundwork for a novel and actionable therapeutic approach. |
